TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02290873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: For induction of maintenance and sedation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive control arm
Study: NCT01178450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtotal parathyroidectomy
Description: The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
Study: NCT02109900

Intervention type: OTHER
Intervention: Serum Progesterone Levels
Study: NCT04460976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation for Adults With Autism and Their Significant Others/Family members (Prisma)
Description: Psychoeducation in groups

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual/standard care
Description: Standard care at disability/habilitation services.
Study: NCT01109914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dukoral
Description: Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:~* Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria\*~* Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dukoral
Description: Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:~* Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria\*~* Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dukoral
Description: Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:~* Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria\*~* Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)
Study: NCT02287623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: patients will receive a tap with liposomal bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: patients will receive a tap with bupivacaine
Study: NCT04739085

Intervention type: DIAGNOSTIC_TEST
Intervention: Defocus curves - Monocular distance visual acuity with trial lenses added to the best correction for distance
Description: The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to distances 30 cm, 40 cm, 60 cm and 80 cm, respectively.

Intervention type: DIAGNOSTIC_TEST
Intervention: wDDART - Monocular near visual acuity using the best correction for distance
Description: The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
Study: NCT03982004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epicutaneous cryoimmunotherapy
Description: Epicutaneous cryoimmunotherapy (EC) treatment includes liquid nitrogen cryotherapy applied for 10 seconds x 2 freeze-thaw cycles. Four treatment areas will be chosen at each treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical imiquimod
Description: Patients will apply the cream directly over the treatment areas and can use up to one packet per day (covers approximately 5 cm x 5 cm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermatologic Quality of Life Index
Description: * 10 questions about how much skin problems has affected the participant's life over the past week~* The scoring of each question is as follows: very much = 3, a lot = 2, a little = 1, not at all = 0, not relevant = 0, and question #7 'prevented work or studying' = 3~* The DLQI is calculated by summing the score of each question resulting in a max of 30 and min of 0. The higher the score, the more quality of life is impaired.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy
Description: * 5 subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns)~* Answers ranging from 0=Not at all to 4 = very much~* Each item is rated on a 5-point Likert scale.~* The higher the score on the social/family well-being and functional well-being indicate higher quality of life~* The lower the score on physical well-being, emotional well-being, and additional concerns indicate higher quality of life

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-lesional GM-CSF
Description: 250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cry-AC
Description: -Device used to give the cryoimmunotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cutaneous tumor biopsy
Description: -Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw for research
Description: -Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
Study: NCT03518788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleur-X
Description: Permanent drainage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleurodesis
Description: Pleurodesis with talc in permanent VATS
Study: NCT03518879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASTHMA-Educator mobile application
Description: The on-site delivered ASTHMA-Educator mobile application.
Study: NCT00259883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: 1 or 2 tablets once a day
Study: NCT01230541

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Udenafil
Description: Daily tablet
Study: NCT05219942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous Glargine insulin (made by Sanofi®) within the first 2 hours of ICU admission. The dose of insulin glargine will be adjusted according to the calculated (eGFR \> 90 dose = 0.27 IU/kg/day, eGFR 60-89 dose = 0.25 IU/kg/day, eGFR \<60 dose = 0.19 IU/kg/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous saline instead of insulin glargine will be given in the control group.
Study: NCT03260088

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunoglobulin G4
Description: IgG4 will be purified from pleural fluids by diethylaminoethyl (DEAE)-cellulose ion exchange nephlometry
Study: NCT03471975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: direct laryngoscope
Description: the trainee use McGrath video laryngoscope as direct laryngoscope the trainee is not allowed to watch the screen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: video laryngoscope
Description: the trainee use McGrath video laryngoscope both trainee and trainer can watch the screen.
Study: NCT00554502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: supportive therapy with: ACE-inhibitor / ARB / Statin
Description: * Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~* ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~* Other antihypertensive medications depending on the clinical decision and following current guidelines.~* Statin therapy~* Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: supportive and immunosuppressive therapy
Description: * supportive therapy as outlined above~* depending on GFR:~  * methylprednisolone and prednisolone~ * cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~* Concomitant medication with the immunosuppressive treatment following current clinical practice
Study: NCT03134170

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacist review of therapy
Description: Patients who are randomized to the pharmacist group will have their treatment reviewed by a pharmacist
Study: NCT01747642

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oncoxin
Description: Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oncoxin
Description: Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suranix
Description: Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
Study: NCT04597736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological collection with nasopharyngeal samples, saliva, blood, stool and urine
Description: Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see Améli.fr) will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel.~For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine.~For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology.
Study: NCT04425187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: gefitinib 250mg (1 tablet), once a day，PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Combined With Gefitinib
Description: Bevacizumab Combined With Gefitinib
Study: NCT05218512

Intervention type: OTHER
Intervention: WB-EMS
Description: The group has been submitted to 2 experimental conditions:~1. At rest with superimposed WB-EMS.~2. During uphill walking exercise with superimposed WB-EMS.
Study: NCT00000299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Study: NCT00004138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study: NCT02734836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Study: NCT02084303

Intervention type: OTHER
Group type: OTHER
Intervention: Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI
Study: NCT00645593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine,
Description: Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine,
Description: Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
Study: NCT00404690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bedside Silo
Description: silo placed at bedside on admission

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative attempt at closure
Description: go the operating room to attempt closure
Study: NCT04169880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HILT
Description: HILT will be performed with BTL 6000 High Intensity Laser (London, UK) which is a therapeutic non-invasive neodymium: yttrium aluminum garnet laser that has a pulsating waveform and 1064 nm wavelength, 12 Watt maximum power and has the ability to penetrate 12 cm.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HILT & EXERCISE
Description: HILT\&Exercise group will receive exercise therapy right after they receive HILT. Both groups will receive treatment for 3 days a week, on alternate days and totally 10 sessions. Patients will be asked not to use analgesic medication throughout the treatment period.
Study: NCT04376320

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: customised ceramic sheets (Group 1)
Description: guided bone regeneration

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: modified sausage technique (Group 2)
Description: guided bone regeneration
Study: NCT00821080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Taken orally at different dose levels depending upon enrollment time period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Taken orally at different dose levels depending upon enrollment time period
Study: NCT00427076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Description: Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR\< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR\<30.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR \<10 1gr Q 4-7 days.
Study: NCT00363948

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Study: NCT02729142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tibial cortical density evaluation
Description: Bone evaluation in transplant patients will be performed by HR-pQCT at baseline (either within 6 months before surgery or within 15 days following surgery) and 6 months post-intervention in order to assess its evolution.
Study: NCT04261075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH5201
Description: Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH5201
Description: Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH5201
Description: Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab Q3W for a maximum of 2 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab Q3W for a maximum of 2 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oleclumab
Description: Oleclumab Q3W for a maximum of 2 years
Study: NCT01890642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J tip
Description: This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: J tip
Description: This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pain Ease Spray
Description: Cold Spray used to anesthetize the skin

Intervention type: OTHER
Group type: OTHER
Intervention: Pain Ease Spray
Description: Cold Spray used to anesthetize the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% buffered lidocaine
Description: Lidocaine placed using Jet Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo cooling spray (normal saline spray)
Description: Normal Saline Sprayed as placebo for Pain Ease spray

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Oral Sucrose used for children \< 1 year

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sucrose
Description: Oral Sucrose used for children \< 1 year

Intervention type: OTHER
Group type: OTHER
Intervention: Sucrose
Description: Oral Sucrose used for children \< 1 year
Study: NCT03765138

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PE/Pramipexole
Description: Experimental: PE/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation.~Pramipexole: In addition to receiving PE as described above, patients will have Pramipexole treatment. Daily dose will be started at 0.25 mg/day and increased by 0.25 mg/day every 3-4 days to a target of 2.5mg day by week 5. Beginning week 6 daily dose will be increased weekly by 0.5 mg/day to a maximum dose of 4mg. Dose will be increased as tolerated unless the patient has achieved remission and will be decreased in the event of intolerable adverse events.
Study: NCT01970501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bucindolol hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol succinate
Study: NCT00801177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 2~200 mg I.V.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 3~400 mg I.V.
Study: NCT01970501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Study: NCT00801177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8 I.V.
Description: Cohort 4~600 mg I.V.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 5~800 mg I.V.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 6~1000 mg I.V.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 1~100 mg I.V.
Study: NCT00794157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg capsules
Description: Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg capsules
Description: Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study: NCT03632733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Tetracycline cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: Clotrimazole cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline and Clotrimazole
Description: Combination cream

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream without active drug ingredients